Company RVL Pharmaceuticals plc

RVLPQ

IE00BF2HDL56

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - OTC Markets Other stock markets 03:51:15 2024-04-19 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-99.00%	-99.97%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Mar. 21	North American Morning Briefing : Investors -2-	DJ

RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

Number of employees: 125

USD in Million	2021	Weight	2022	Weight	Delta
Pharmaceutical Products 100.0 %	18	100.0 %	50	100.0 %	+184.10%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	18	100.0 %	50	100.0 %	+184.10%

Managers	Title	Age	Since
Sergio Alegre CMP	Compliance Officer	-	16-07-31
James Schaub COO	Chief Operating Officer	42	15-12-31
Michael Depetris AUD	Comptroller/Controller/Auditor	-	22-04-17
Jarret Miller HRO	Human Resources Officer	-	15-12-31
Christopher Klein LAW	General Counsel	60	13-11-30

Members of the board	Title	Age	Since
Gregory Cowan BRD	Director/Board Member	70	18-12-31
Alisa Lask BRD	Director/Board Member	53	22-08-09
Michael DeBiasi BRD	Director/Board Member	48	19-09-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	111,406,043	107,306,425 ( 96.32 %)	0	96.32 %

Name	Equities	%	Valuation
Armistice Capital LLC 9.558 %	10,648,000	9.558 %	- $
Athyrium Capital Management LP 7.315 %	8,148,832	7.315 %	- $
Brian Markison 2.099 %	2,338,242	2.099 %	- $
Altchem Ltd. 1.061 %	1,182,243	1.061 %	- $
James Schaub 0.4547 %	506,521	0.4547 %	- $
XTX Topco Ltd. 0.1621 %	180,566	0.1621 %	- $
Gregory Cowan 0.0449 %	50,055	0.0449 %	- $
Michael DeBiasi 0.0359 %	40,000	0.0359 %	- $
Alisa Lask 0.0202 %	22,557	0.0202 %	- $
Simplex Trading LLC 0.006194 %	6,900	0.006194 %	- $

RVL Pharmaceuticals Plc

400 Crossing Boulevard

08807, Bridgewater

+908 809 1300

http://www.rvlpharma.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
RVL PHARMACEUTICALS PLC	-99.97%	111
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
BIOGEN INC.	-21.76%	29.48B
UCB	+56.91%	25.43B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	15.59B
INCYTE CORPORATION	-18.49%	11.49B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.75B

Biopharmaceuticals